AstraZeneca may face a new fine of $8 million in China, involving breast cancer drugs.

On April 29th, local time in the UK, AstraZeneca revealed at the latest quarterly financial report meeting that the company may face a new fine in China, amounting to $8 million. AstraZeneca stated that the latest fine involves unpaid taxes for the import of breast cancer drug Enhertu. The company had previously stated at the last quarterly financial report meeting that it would face a fine of up to $4.5 million for unpaid taxes on another two anti-cancer drugs, Imfinzi and Imjudo.